- Home
- GEG vs NTRB Comparison
GEG vs NTRB Comparison
Compare GEG & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEG
- NTRB
- Stock Information
- Founded
- GEG 1994
- NTRB 2016
- Country
- GEG United States
- NTRB United States
- Employees
- GEG N/A
- NTRB N/A
- Industry
- GEG Computer Software: Prepackaged Software
- NTRB Industrial Specialties
- Sector
- GEG Technology
- NTRB Health Care
- Exchange
- GEG Nasdaq
- NTRB Nasdaq
- Market Cap
- GEG 55.6M
- NTRB 46.4M
- IPO Year
- GEG N/A
- NTRB N/A
- Fundamental
- Price
- GEG $1.81
- NTRB $4.11
- Analyst Decision
- GEG
- NTRB
- Analyst Count
- GEG 0
- NTRB 0
- Target Price
- GEG N/A
- NTRB N/A
- AVG Volume (30 Days)
- GEG 15.6K
- NTRB 26.3K
- Earning Date
- GEG 02-11-2025
- NTRB 12-04-2024
- Dividend Yield
- GEG N/A
- NTRB N/A
- EPS Growth
- GEG N/A
- NTRB N/A
- EPS
- GEG N/A
- NTRB N/A
- Revenue
- GEG $18,516,000.00
- NTRB $2,021,771.00
- Revenue This Year
- GEG N/A
- NTRB N/A
- Revenue Next Year
- GEG N/A
- NTRB N/A
- P/E Ratio
- GEG N/A
- NTRB N/A
- Revenue Growth
- GEG 83.09
- NTRB N/A
- 52 Week Low
- GEG $1.70
- NTRB $2.22
- 52 Week High
- GEG $2.12
- NTRB $9.60
- Technical
- Relative Strength Index (RSI)
- GEG 49.69
- NTRB 44.78
- Support Level
- GEG $1.79
- NTRB $3.90
- Resistance Level
- GEG $1.82
- NTRB $5.16
- Average True Range (ATR)
- GEG 0.02
- NTRB 0.33
- MACD
- GEG -0.00
- NTRB -0.01
- Stochastic Oscillator
- GEG 64.29
- NTRB 27.04
About GEG Great Elm Group Inc.
Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.